Announcement • Jul 02
Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) announces an Equity Buyback for CNY 100 million worth of its shares. Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) announces a share repurchase program. Under the program, the company will repurchase not more than CNY 100 million worth of its ordinary A shares. The shares will be repurchased at a price not exceeding CNY 58.00 per share. The company will use its own funds and special loans for repurchase purpose. All the shares repurchased will be used for cancellation and reduction of the company's registered capital. The plan is subject to shareholders' approval. The plan will be valid for 12 months from the date the Company's shareholders' meeting approves the share repurchase plan. Announcement • Jun 30
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report First Half, 2026 Results on Aug 28, 2026 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that they will report first half, 2026 results on Aug 28, 2026 Valuation Update With 7 Day Price Move • May 21
Investor sentiment deteriorates as stock falls 32% After last week's 32% share price decline to CN¥45.45, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 36x in the Pharmaceuticals industry in China. Total loss to shareholders of 31% over the past three years. Declared Dividend • May 18
Dividend of CN¥1.00 announced Shareholders will receive a dividend of CN¥1.00. Ex-date: 22nd May 2026 Payment date: 22nd May 2026 Dividend yield will be 2.2%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (55% earnings payout ratio) and cash flows (83% cash payout ratio). The dividend has increased by an average of 49% per year over the past 9 years. However, payments have been volatile during that time. Earnings per share has grown by 39% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 22
Full year 2025 earnings released: EPS: CN¥2.83 (vs CN¥1.38 in FY 2024) Full year 2025 results: EPS: CN¥2.83 (up from CN¥1.38 in FY 2024). Revenue: CN¥2.47b (up 27% from FY 2024). Net income: CN¥695.9m (up 106% from FY 2024). Profit margin: 28% (up from 17% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Apr 22
Shenyang Xingqi Pharmaceutical Co.,Ltd., Annual General Meeting, May 13, 2026 Shenyang Xingqi Pharmaceutical Co.,Ltd., Annual General Meeting, May 13, 2026, at 14:30 China Standard Time. Location: 30F, Tower B, No. 125, Qingnian Avenue, Shenhe District, Shenyang, Liaoning China Announcement • Mar 31
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q1, 2026 Results on Apr 28, 2026 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 Buy Or Sell Opportunity • Jan 21
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 14% to CN¥82.72. The fair value is estimated to be CN¥67.85, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 41%. Announcement • Dec 31
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 22, 2026 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 22, 2026 Buy Or Sell Opportunity • Oct 29
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 27% to CN¥82.01. The fair value is estimated to be CN¥68.08, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 41%. Announcement • Sep 30
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025 Reported Earnings • Aug 31
Second quarter 2025 earnings released: EPS: CN¥0.77 (vs CN¥0.54 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.77 (up from CN¥0.54 in 2Q 2024). Revenue: CN¥626.6m (up 16% from 2Q 2024). Net income: CN¥188.9m (up 40% from 2Q 2024). Profit margin: 30% (up from 25% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year whereas the company’s share price has increased by 27% per year. Buy Or Sell Opportunity • Aug 13
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 15% to CN¥64.34. The fair value is estimated to be CN¥52.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 21%. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥66.26, the stock trades at a trailing P/E ratio of 36.2x. Average trailing P/E is 36x in the Pharmaceuticals industry in China. Total returns to shareholders of 110% over the past three years. Buy Or Sell Opportunity • Jul 28
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 6.5% to CN¥62.55. The fair value is estimated to be CN¥52.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 21%. Announcement • Jul 02
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 Announcement • May 29
Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 850 million in funding Shenyang Xingqi Pharmaceutical Co.,Ltd. announced a private placement to issue 73,604,683 A shares at an issue price of not be less than eighty percent of the average trading price of the company's stocks over the twenty trading days prior to the pricing reference date for gross proceeds of CNY 850,000,000 on May 27, 2025. The transaction has been approved by 9th meeting of the 5th board of directors of the company and must be approved by the shareholders' meeting of the Company, reviewed and approved by the Shenzhen Stock Exchange, and receive a registration approval decision from the China Securities Regulatory Commission before implementation. After completing the above approval procedures, the Company will apply to the Shenzhen Stock Exchange and the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. for the issuance, registration, and listing of the shares, completing all reporting and approval procedures for this issuance of shares to specific targets. There is uncertainty regarding whether the above reporting matters will receive registration approval and the timing of obtaining such approval. Investors are advised to pay attention to the approval risks. The shares subscribed by the issuance targets in this offering shall not be transferred within 6 months from the end of the issuance. Declared Dividend • May 17
Dividend of CN¥1.00 announced Shareholders will receive a dividend of CN¥1.00. Ex-date: 22nd May 2025 Payment date: 22nd May 2025 Dividend yield will be 1.9%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by both earnings (58% earnings payout ratio) and cash flows (83% cash payout ratio). The dividend has increased by an average of 48% per year over the past 8 years. However, payments have been volatile during that time. Earnings per share has grown by 72% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • May 16
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Final Cash Dividend Plan on A Shares for 2024, Payable on 22 May 2025 Shenyang Xingqi Pharmaceutical Co.,Ltd. at its Annual General Meeting held on 13 May 2025 approved the final cash dividend of CNY 10.00000000 per 10 shares (tax included) on A shares for 2024. Record date is 21 May 2025, Ex-date is 22 May 2025 and Payment date is 22 May 2025. Announcement • Apr 23
Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Final Dividend for the Year 2024 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced on 22 April 2025 the profit distribution proposal for 2024 as follows: Cash dividend/10 shares (tax included): CNY 10.00. Reported Earnings • Apr 22
Full year 2024 earnings released: EPS: CN¥1.94 (vs CN¥1.38 in FY 2023) Full year 2024 results: EPS: CN¥1.94 (up from CN¥1.38 in FY 2023). Revenue: CN¥1.94b (up 32% from FY 2023). Net income: CN¥338.1m (up 41% from FY 2023). Profit margin: 17% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 22
Shenyang Xingqi Pharmaceutical Co.,Ltd., Annual General Meeting, May 13, 2025 Shenyang Xingqi Pharmaceutical Co.,Ltd., Annual General Meeting, May 13, 2025, at 14:30 China Standard Time. Location: 2F, Building E1, No. 68, Sishui Subdistrict, Hunnan District, Shenyang China Announcement • Mar 31
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Announcement • Dec 31
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 22, 2025 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 22, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.70 (vs CN¥0.54 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.70 (up from CN¥0.54 in 3Q 2023). Revenue: CN¥547.5m (up 31% from 3Q 2023). Net income: CN¥121.4m (up 28% from 3Q 2023). Profit margin: 22% (in line with 3Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 10% per year. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 28% After last week's 28% share price decline to CN¥88.89, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 57% over the past three years. Announcement • Sep 30
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 New Risk • Sep 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 144% Cash payout ratio: 219% Valuation Update With 7 Day Price Move • Sep 26
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥82.34, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 16x in the Pharmaceuticals industry in China. Total returns to shareholders of 30% over the past three years. Valuation Update With 7 Day Price Move • Sep 04
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥80.57, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total returns to shareholders of 54% over the past three years. Announcement • Aug 30
Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Profit Distribution for First Half of 2024 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced on 29 August 2024 the profit distribution proposal for the first half of 2024 as follows: Cash dividend per 10 shares (tax included): CNY 5.00000000. Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.77 (vs CN¥0.39 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.77 (up from CN¥0.39 in 2Q 2023). Revenue: CN¥541.9m (up 36% from 2Q 2023). Net income: CN¥134.6m (up 97% from 2Q 2023). Profit margin: 25% (up from 17% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Aug 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Xianmei Xu was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. New Risk • Jul 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 181% Cash payout ratio: 301% Minor Risk Share price has been volatile over the past 3 months (7.1% average weekly change). Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥115, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 136% over the past three years. Announcement • Jun 29
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 Declared Dividend • May 17
Dividend of CN¥3.00 announced Shareholders will receive a dividend of CN¥3.00. Ex-date: 22nd May 2024 Payment date: 22nd May 2024 Dividend yield will be 1.4%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is not covered by earnings (196% earnings payout ratio) nor is it covered by cash flows (488% cash payout ratio). The dividend has increased by an average of 82% per year over the past 7 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 118% to bring the payout ratio under control. EPS is expected to grow by 148% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Announcement • May 16
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend per 10 shares (tax included): CNY 30.00000000. Record date: 21 May 2024, Ex-date: 22 May 2024. Payment date: 22 May 2024. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.16 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.28 (up from CN¥0.16 in 1Q 2023). Revenue: CN¥349.9m (up 22% from 1Q 2023). Net income: CN¥34.7m (up 80% from 1Q 2023). Profit margin: 9.9% (up from 6.8% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 20
Shenyang Xingqi Pharmaceutical Co.,Ltd., Annual General Meeting, May 13, 2024 Shenyang Xingqi Pharmaceutical Co.,Ltd., Annual General Meeting, May 13, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Shenyang, Liaoning China Reported Earnings • Apr 18
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥1.93 (up from CN¥1.72 in FY 2022). Revenue: CN¥1.47b (up 17% from FY 2022). Net income: CN¥240.0m (up 13% from FY 2022). Profit margin: 16% (in line with FY 2022). Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 30
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Announcement • Jan 09
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections Shenyang Xingqi Pharmaceutical Co.,Ltd. announced at first extraordinary general meeting held on January 5, 2024, the shareholders elected Liu Jidong as non-independent director; Xu Xianmei and Kong Xiaoyan as independent directors; Qu Xiaoyu as non-employee supervisor of the company. Announcement • Dec 29
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2023 results on Apr 19, 2024 Reported Earnings • Oct 24
Third quarter 2023 earnings released: EPS: CN¥0.76 (vs CN¥0.66 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.76 (up from CN¥0.66 in 3Q 2022). Revenue: CN¥419.4m (up 3.9% from 3Q 2022). Net income: CN¥94.6m (up 15% from 3Q 2022). Profit margin: 23% (up from 20% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year and the company’s share price has also increased by 18% per year. New Risk • Oct 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 99% Dividend per share is over 6x cash flows per share. Minor Risk Profit margins are more than 30% lower than last year (13% net profit margin). Announcement • Sep 30
Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 24, 2023 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that they will report Q3, 2023 results on Oct 24, 2023 Announcement • Sep 19
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Interim Dividend on A Shares for the Year 2023, Payable on 22 September 2023 Shenyang Xingqi Pharmaceutical Co.,Ltd. announced interim cash dividend/10 shares (tax included) of CNY 10.00000000 on A shares for the year 2023. Record date is September 21, 2023. Ex-date is September 22, 2023. Payment date is September 22, 2023. Announcement • Sep 15
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Cash Interim Profit Distribution Plan for 2023 Shenyang Xingqi Pharmaceutical Co.,Ltd. held its 3rd Extraordinary General Meeting of 2023 on 13 September 2023 were approved 2023 interim profit distribution plan as Cash dividend/10 shares (tax included): CNY 10.00000000. Board Change • Sep 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Chairman of the Board - Newsun was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Aug 30
Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Dividend for the First Half of 2023 Shenyang Xingqi Pharmaceutical Co.,Ltd. proposed on 29 August 2023 the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 10.00000000. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥166, the stock trades at a trailing P/E ratio of 69.3x. Average trailing P/E is 34x in the Pharmaceuticals industry in China. Total returns to shareholders of 80% over the past three years. Reported Earnings • Apr 24
Full year 2022 earnings released: EPS: CN¥2.41 (vs CN¥2.39 in FY 2021) Full year 2022 results: EPS: CN¥2.41 (up from CN¥2.39 in FY 2021). Revenue: CN¥1.25b (up 22% from FY 2021). Net income: CN¥211.7m (up 8.7% from FY 2021). Profit margin: 17% (down from 19% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Board Change • Apr 14
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Non-Independent Director Gaozhi Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Mar 02
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥122, the stock trades at a trailing P/E ratio of 44.6x. Average trailing P/E is 38x in the Pharmaceuticals industry in China. Total returns to shareholders of 25% over the past three years. Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥146, the stock trades at a trailing P/E ratio of 53.4x. Average trailing P/E is 34x in the Pharmaceuticals industry in China. Total returns to shareholders of 86% over the past three years. Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥123, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 53% over the past three years. Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improved over the past week After last week's 25% share price gain to CN¥118, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 44% over the past three years. Buying Opportunity • Nov 01
Now 21% undervalued Over the last 90 days, the stock is up 14%. The fair value is estimated to be CN¥133, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 34% over the last 3 years. Earnings per share has grown by 64%. Revenue is forecast to grow by 80% in 2 years. Earnings is forecast to grow by 204% in the next 2 years. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.93 (vs CN¥0.90 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.93 (up from CN¥0.90 in 3Q 2021). Revenue: CN¥403.7m (up 31% from 3Q 2021). Net income: CN¥82.2m (up 8.3% from 3Q 2021). Profit margin: 20% (down from 25% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • Sep 18
Shenyang Xingqi Pharmaceutical Co.,Ltd Announces Interim Dividend on A Shares for the Year 2021, Payable on September 23, 2022 Shenyang Xingqi Pharmaceutical Co.,Ltd announced interim cash dividend/10 shares (tax included) of CNY 5.00000000 on A shares for the year 2021. Record date is 22 September 2022. Ex-date is 23 September 2022. Payment date is 23 September 2022. Announcement • Sep 15
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Interim Cash Dividend for 2022 Shenyang Xingqi Pharmaceutical Co.,Ltd announced that at the Extraordinary General Meeting of 2022 held on 13 September 2022 approved interim Cash dividend/10 shares (tax included) of CNY 5.00000000 for 2022. Announcement • Aug 30
Shenyang Xingqi Pharmaceutical Announces Profit Distribution Proposal for the First Half of 2022 Shenyang Xingqi Pharmaceutical Co.,Ltd announced on 29 August 2022 the profit distribution proposal for the first half of 2022. Cash dividend/10 shares (tax included): CNY 5.00000000. Reported Earnings • Aug 29
Second quarter 2022 earnings released: EPS: CN¥0.53 (vs CN¥0.59 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.53 (down from CN¥0.59 in 2Q 2021). Revenue: CN¥298.6m (up 17% from 2Q 2021). Net income: CN¥46.5m (down 1.0% from 2Q 2021). Profit margin: 16% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 46%, compared to a 22% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 27
Investor sentiment deteriorated over the past week After last week's 22% share price decline to CN¥131, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 137% over the past three years. Valuation Update With 7 Day Price Move • May 31
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥140, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total returns to shareholders of 187% over the past three years. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improved over the past week After last week's 27% share price gain to CN¥105, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 30x in the Pharmaceuticals industry in China. Total returns to shareholders of 91% over the past three years. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.40 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.84 (up from CN¥0.40 in 1Q 2021). Revenue: CN¥302.0m (up 46% from 1Q 2021). Net income: CN¥74.2m (up 123% from 1Q 2021). Profit margin: 25% (up from 16% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Announcement • Apr 21
Shenyang Xingqi Pharmaceutical Co.,Ltd Proposes Final Cash Dividend for the Year 2021 Shenyang Xingqi Pharmaceutical Co.,Ltd proposed final cash dividend per ten shares (tax included) of CNY 4.00000000 for the year 2021. Reported Earnings • Apr 20
Full year 2021 earnings released: EPS: CN¥2.39 (vs CN¥1.09 in FY 2020) Full year 2021 results: EPS: CN¥2.39 (up from CN¥1.09 in FY 2020). Revenue: CN¥1.03b (up 49% from FY 2020). Net income: CN¥194.7m (up 121% from FY 2020). Profit margin: 19% (up from 13% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥114, the stock trades at a trailing P/E ratio of 49.3x. Average trailing P/E is 36x in the Pharmaceuticals industry in China. Total returns to shareholders of 597% over the past three years. Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥117, the stock trades at a trailing P/E ratio of 50.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total returns to shareholders of 562% over the past three years. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.47 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥308.0m (up 32% from 3Q 2020). Net income: CN¥75.9m (up 98% from 3Q 2020). Profit margin: 25% (up from 17% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has increased by 100% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥122, the stock trades at a trailing P/E ratio of 65.9x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total returns to shareholders of 669% over the past three years. Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥110, the stock trades at a trailing P/E ratio of 58.2x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total returns to shareholders of 603% over the past three years. Reported Earnings • Aug 27
Second quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.32 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥255.2m (up 66% from 2Q 2020). Net income: CN¥46.9m (up 82% from 2Q 2020). Profit margin: 18% (up from 17% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 86% per year whereas the company’s share price has increased by 84% per year. Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment deteriorated over the past week After last week's 21% share price decline to CN¥90.83, the stock trades at a trailing P/E ratio of 56.2x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total returns to shareholders of 404% over the past three years. Valuation Update With 7 Day Price Move • Jul 03
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CN¥128, the stock trades at a trailing P/E ratio of 79x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total returns to shareholders of 605% over the past three years. Announcement • May 15
Shenyang Xingqi Pharmaceutical Co., Ltd. Announces Final Cash Dividend for the Year 2020, Payable on 21 May 2021 Shenyang Xingqi Pharmaceutical Co., Ltd. announced final cash dividend (tax included) of CNY 2.50 per 10 shares for the year 2020, payable on 21 May 2021. Record date is 20 May 2021 and ex-date is 21 May 2021. Reported Earnings • Apr 20
Full year 2020 earnings released: EPS CN¥1.09 (vs CN¥0.45 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥688.7m (up 27% from FY 2019). Net income: CN¥88.0m (up 145% from FY 2019). Profit margin: 13% (up from 6.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has increased by 78% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 09
Shenyang Xingqi Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021 Shenyang Xingqi Pharmaceutical Co., Ltd. announced that they will report fiscal year 2020 results on Apr 20, 2021 Is New 90 Day High Low • Jan 28
New 90-day low: CN¥93.15 The company is down 33% from its price of CN¥140 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Announcement • Jan 09
Shenyang Xingqi Pharmaceutical Co., Ltd. Approves Directorate Elections Shenyang Xingqi Pharmaceutical Co., Ltd. at its EGM held on January 7, 2021 approved election of Cheng Yanan; Yang Qian; Liu Gaozhi as non-independent directors. The board elected Dai Xiaobin as independent director. The board elected Xu Qi and Qu Xiaoyu as a non-employee supervisors. Is New 90 Day High Low • Dec 25
New 90-day low: CN¥107 The company is down 22% from its price of CN¥137 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Is New 90 Day High Low • Nov 18
New 90-day low: CN¥124 The company is down 23% from its price of CN¥162 on 20 August 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 9.0% over the same period.